Business Wire

美国食品药品管理局(FDA)向Samsung Bioepis与Organon的HADLIMA™ (adalimumab-bwwd ...

韩国仁川和新泽西州泽西市--(BUSINESS WIRE)--(美国商业资讯)-- Samsung Bioepis Co., Ltd.与Organon & Co. (NYSE: OGN)今日宣布，美国食品药品管理局(FDA)已认定HADLIMA™ (adalimumab-bwwd)的高浓度和低浓度（40 mg/0.4 mL、40 mg/0.8 mL）自动注射器及高浓度预充式注射器为Humira ® ...
Nasdaq

Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License ...

INCHEON, South Korea and JERSEY CITY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the U.S. Food and Drug Administration (FDA) ...
Seeking Alpha

Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License ...

--Samsung Bioepis Co., Ltd. and Organon& Co. today announced that the U.S. Food and Drug Administration has accepted for review the Supplemental Biologics License Application for the ...
Seeking Alpha

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung ...

“This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...